In the June issue of Inside Precision Medicine, Alan Wookey, Vice President Companion Diagnostics and Q2 Solutions’ scientific advisor, explores the evolution of companion diagnostics (CDx) since the landmark Herceptest approval in 1998. Alan highlights how precision medicine has transformed patient care and the critical role of CDx in clinical trials and treatments.
The article delves into CDx development paths, the impact of recent regulatory changes, and the future of precision medicine beyond oncology. Learn about the key considerations for successful CDx development and the latest advancements in diagnostic technology.
Click here to read the full article.
